The impact of genomic and proteomic technologies on the development of new cancer drugs.
Workman
P
P
Cancer Research UK, Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, UK.
D000970:Antineoplastic Agents / Q000494:pharmacology*; D005260:Female; D005544:Forecasting; D020869:Gene Expression Profiling; D015316:Genetic Therapy / Q000592:standards* / Q000639:trends; D023281:Genomics / Q000592:standards* / Q000639:trends; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D010597:Pharmacogenetics; D020543:Proteome / Q000235:genetics / Q000494:pharmacology*; D012680:Sensitivity and Specificity; D013678:Technology, Pharmaceutical / Q000592:standards / Q000639:trends; D006113:United Kingdom
D000970:Antineoplastic Agents; D020543:Proteome